Vanderbilt Clinical Trials

A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Purpose

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: - How EoE makes one feel - EoE symptoms - How EoE affects quality-of-life - How EoE impacts aspects of daily life - How difficult it is to swallow - How EoE symptoms have changed throughout the study

Condition

Eosinophilic Esophagitis (EoE)

Eligibility

Eligible Ages: Over 12 Years
Eligible Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Initiating treatment with DUPIXENT® for EoE according to the USPI 2. Able to understand and complete registry-related questionnaires (including adolescents)

Exclusion Criteria

Patients who have a contraindication to DUPIXENT® according to the USPI 2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment 3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator) NOTE: Other protocol defined inclusion/exclusion criteria apply

Study Design

Phase
Study Type: Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective

Arm Groups

Arm	Description	Assigned Intervention
EoE Patients treated with DUPIXENT®		Drug: dupilumab No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor. Other names: DUPIXENT® REGN668 SAR231893

Recruiting Locations

Vanderbilt University Medical Center
Nashville 4644585, Tennessee 4662168 37232

More Details

Status: Recruiting
Sponsor: Regeneron Pharmaceuticals

Study Contact

Clinical Trials Administrator
844-734-6643
clinicaltrials@regeneron.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.